Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases.

Scientific reports - 17 Feb 2017

Zhang Guowei, Cheng Ruirui, Zhang Zengli, Jiang Tao, Ren Shengxiang, Ma Zhiyong, Zhao Sha, Zhou Caicun, Zhang Jun

Abstract excerpt

Whether bisphosphonates could enhance the effect of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancer (NSCLC) patients with EGFR mutation and bone metastases (BM) remains unknown. EGFR mutation status were collected from 1560 patients with NSCLC and BM. 356 NSCLC patients with EGFR mutation and BM were identified. Among them, 91 patients received EGFR-TKIs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Neoplasms
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diphosphonates

Share to Disease-Free Survival

Share to Drug Synergism

Share to Multivariate Analysis

Share to Protein Kinase Inhibitors

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 28211502
DOI: 10.1038/srep42979
PMCID: PMC5314405

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases.PMID 28211502Read ↗

Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study.Semantic proximity Read ↗

Assessing EGFR-mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy.Semantic proximity Read ↗

A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation.Semantic proximity Read ↗

Clinical Implications of Isolated Bone Failure Without Systemic Disease Progression During EGFR-TKI Treatment.Semantic proximity Read ↗

Prognosis of different bone metastases patterns in EGFR-mutant advanced lung adenocarcinoma patientsSemantic proximity Read ↗

The Efficacy of First-Generation EGFR-TKI Combined With Brain Radiotherapy as the First-Line Treatment for Lung Adenocarcinoma Patients With Brain Metastases and EGFR Sensitive Mutations: A Retrospective study.Semantic proximity Read ↗

[Predictive relevance of KRAS mutational status in bone metastatic lung adenocarcinoma treated with bisphosphonate therapy].Semantic proximity Read ↗

Radiotherapy effects on brain/bone metastatic adenocarcinoma lung cancer and the importance of EGFR mutation test.Semantic proximity Read ↗

Femoral bone metastasis is a poor prognostic factor in osimertinib-treated patients with EGFR-mutated non-small cell lung cancer: a retrospective, multicenter studySemantic proximity Read ↗

Femoral bone metastasis is a poor prognostic factor in osimertinib-treated patients with EGFR-mutated non-small cell lung cancerSemantic proximity Read ↗

Zoledronic acid increases the antitumor effect of gefitinib treatment for non-small cell lung cancer with EGFR mutations.Semantic proximity Read ↗

Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.